Case Report: Enfortumab vedotin and pembrolizumab in androgen pathway modulation-naive prostate cancer with high-volume metastatic burden
In recent history, enfortumab vedotin (EV) in combination with pembrolizumab (EV-pembrolizumab) has emerged at the front line of treatment in urothelial carcinoma for its marked efficacy and tolerability measured against prior standard-of-care chemotherapies. Advanced prostate cancer remains a universally incurable disease. We present, for the first time in the literature, a case of marked objective and clinical response to EV-pembrolizumab in androgen pathway modulator-naive prostate cancer with high-volume metastatic burden, offering unique insight and consideration for a new therapeutic approach in a challenging and common advanced disease.
Authors
- Joshua T. Kowalczyk (ORCID: https://orcid.org/0000-0002-2212-7809)
- Christopher J. Hoimes (ORCID: https://orcid.org/0000-0001-8980-2410)
Institutions
- Duke University (US)
- Duke Medical Center (US)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2026-11-16
- DOI
- https://doi.org/10.3389/fonc.2026.1937935
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00